Corvus Pharmaceuticals, Inc.
For the period ended Jun 11, 2026. Filed Apr 24, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 11, 2026 · Filed Apr 24, 2026
Contents
PAY VERSUS PERFORMANCE
Pay Versus Performance Table
The following table sets forth information concerning the compensation provided to our NEOs and certain measures of Company performance in the years ended December 31, 2025, 2024 and 2023, for services to our Company in all capacities. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the fiscal years shown.
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | Average Summary | | Average | | Value of Initial Fixed | | |
| | | Summary | | Compensation | | Compensation Table | | Compensation | | $100 investment Based | | |
| | | Compensation Table | | Actually Paid | | Total for Non-PEO | | Actually Paid | | on Total Shareholder | | Net Loss |
| Year | | Total for PEO ($) | | to PEO ($) (1) | | NEOs ($) | | to Non-PEO NEOs ($) (1) | | Return ("TSR") ($) (2) | | ($ in millions) |
| | | | | | | | | | | | | |
| 2025 | 7,031,566 | 7,325,075 | 3,184,632 | 3,238,187 | 905.88 | (15.3) | ||||||
| 2024 | 3,073,170 | 7,473,091 | 1,592,174 | 2,786,445 | 629.41 | (62.3) | ||||||
| 2023 | | 1,321,351 | | 2,573,371 | | 638,510 | | 928,436 | | 207.06 | | (27.0) |
| (1) | Amounts represent compensation actually paid (“CAP”) to our CEO, Richard Miller, M.D., who was our Principal Executive Officer or “PEO” for each of the two years shown, and the average CAP to our remaining NEOs or “Non-PEO NEOs” for the relevant fiscal year, as determined under SEC rules, which includes Leiv Lea and William B. Jones, Ph.D. |
Amounts represent the Summary Compensation Table Total Compensation for the applicable fiscal year adjusted as follows:
| | | | |
|---|---|---|---|
| Fiscal Year ("FY") | 2025 | ||
| | | | Average non- |
| | PEO | | PEO NEOs |
| Deduction for ASC 718 Fair Value as of Grant Date Reported under the Option Awards Columns in the Summary Compensation Table | (6,989,000) | (2,795,600) | |
| Increase based on ASC 718 Fair Value of Awards Granted during the FY that Remain Unvested as of FY End (“FYE”) | 5,907,717 | 2,363,087 | |
| Increase based on ASC 718 Fair Value of Awards Granted during the FY that Vested during the FY as of Vesting Date | — | | — |
| Increase/deduction based on ASC 718 Fair Value of Outstanding Unvested Prior FY Awards as of FYE Compared to Valuation as of Prior FYE | 1,473,617 | | 543,004 |
| Increase/deduction based on ASC 718 Fair Value of Prior FY Awards that Vested during the FY as of Vesting Date Compared to Valuation as of Prior FYE | (98,825) | | (56,936) |
| Total Adjustments | 293,509 | | 53,555 |
| (2) | TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our company’s share price at the end and the beginning of the measurement period by our company’s share price at the beginning of the measurement period. The Company’s share price at the beginning of the measurement period is the closing share price of $0.85 on December 30, 2022, the last trading day of fiscal year 2022, and the Company’s share price at end of the measurement period is the closing share price of $7.70 on December 31, 2025, the last trading day of fiscal year 2025. No dividends were paid on our common stock in 2023, 2024 or 2025. |
Description of Certain Relationships between Information Presented in the Pay versus Performance Table
While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for a particular
year. In accordance with SEC rules, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.